Regan Woodham
Acute Care · Dothan, ALNPI 1467064089
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 419 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,300, more than ten times the $19 reported in 2021. Among acute care clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Amgen$608
- Takeda Pharmaceuticals U.S.A., Inc.$602
- Sanofi$548
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,65999%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $1,331 |
| AstraZeneca | 49 | $1,276 |
| Boehringer Ingelheim | 51 | $1,222 |
| Amgen | 32 | $608 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $602 |
| Sanofi | 26 | $548 |
| Regeneron Healthcare Solutions, Inc. | 27 | $524 |
| Grifols USA, LLC | 19 | $402 |
| Mylan Specialty L.p. | 19 | $343 |
| United Therapeutics Corporation | 16 | $334 |
| Jazz Pharmaceuticals Inc. | 10 | $246 |
| Axsome Therapeutics, Inc. | 9 | $196 |
| Electromed, Inc. | 13 | $156 |
| Viatris Specialty LLC | 7 | $145 |
| Harmony Biosciences LLC | 7 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Merck | 4 | $83 |
| Philips North America LLC | 4 | $78 |
| Verona Pharma, Inc. | 4 | $74 |
| Vifor Pharma, Inc. | 3 | $68 |
| Actelion Pharmaceuticals US, Inc. | 3 | $60 |
| 3b Medical, Inc. | 4 | $57 |
| Lilly USA, LLC | 1 | $49 |
| Insmed, Inc. | 2 | $45 |
| Genentech USA, Inc. | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| Inogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,748 in reported general payments places this provider in the 90th percentile of 711 acute care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 658 | $511,406 |
| OfevNintedanib Esylate | 23 | $287,318 |
| TezspireTezepelumab-Ekko | 25 | $109,872 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 134 | $109,270 |
| Fasenra PenBenralizumab | 17 | $93,040 |
| Breo ElliptaFluticasone/Vilanterol | 110 | $58,272 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 85 | $43,535 |
| Spiriva RespimatTiotropium Bromide | 46 | $24,299 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $15,486 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $13,679 |
| EliquisApixaban | 11 | $10,922 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 71 | $9,698 |
| BreynaBudesonide/Formoterol Fumarate | 50 | $7,237 |
| Wixela InhubFluticasone Propion/Salmeterol | 39 | $5,390 |
| Arnuity ElliptaFluticasone Furoate | 21 | $5,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,331 | $618,229874 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,222 | $327,10391 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,276 | $232,820205 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 711 acute care providers in Alabama.
Other acute care in Dothan
- Rachel PrytulaDothan$14K
- Paige HarrisMontgomery$465K
- Coretta CollinsBirmingham$77K
- Debra DavisFoley$31K
- Leslie GastonMobile$22K
- Gwendolyn HooperTuscaloosa$16K
- Jennifer UmbargerMobile$14K
- April KlarHuntsville$13K
- Cameron StephensonBirmingham$13K
- Jonathan McCraryBirmingham$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.